🚀 VC round data is live in beta, check it out!
Jiangsu Hengrui Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jiangsu Hengrui Pharma and similar public comparables like Zoetis, UCB, CSL, Takeda Pharmaceuticals and more.
Jiangsu Hengrui Pharma Overview
About Jiangsu Hengrui Pharma
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
Founded
1997
HQ
Employees
20.2K
Website
Sectors
Financials (LTM)
EV
$47B
Jiangsu Hengrui Pharma Financials
Jiangsu Hengrui Pharma reported last 12-month revenue of $5B and EBITDA of $1B.
In the same LTM period, Jiangsu Hengrui Pharma generated $4B in gross profit, $1B in EBITDA, and $1B in net income.
Revenue (LTM)
Jiangsu Hengrui Pharma P&L
In the most recent fiscal year, Jiangsu Hengrui Pharma reported revenue of $5B and EBITDA of $1B.
Jiangsu Hengrui Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 24% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jiangsu Hengrui Pharma Stock Performance
Jiangsu Hengrui Pharma has current market cap of $52B, and enterprise value of $47B.
Market Cap Evolution
Jiangsu Hengrui Pharma's stock price is $7.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47B | $52B | -0.0% | XXX | XXX | XXX | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJiangsu Hengrui Pharma Valuation Multiples
Jiangsu Hengrui Pharma trades at 9.8x EV/Revenue multiple, and 34.1x EV/EBITDA.
EV / Revenue (LTM)
Jiangsu Hengrui Pharma Financial Valuation Multiples
As of March 31, 2026, Jiangsu Hengrui Pharma has market cap of $52B and EV of $47B.
Equity research analysts estimate Jiangsu Hengrui Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Hengrui Pharma has a P/E ratio of 44.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $52B | XXX | $52B | XXX | XXX | XXX |
| EV (current) | $47B | XXX | $47B | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBITDA | 34.1x | XXX | 33.7x | XXX | XXX | XXX |
| EV/EBIT | 36.3x | XXX | 37.5x | XXX | XXX | XXX |
| EV/Gross Profit | 11.3x | XXX | 11.8x | XXX | XXX | XXX |
| P/E | 44.7x | XXX | 46.9x | XXX | XXX | XXX |
| EV/FCF | 34.5x | XXX | 33.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jiangsu Hengrui Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jiangsu Hengrui Pharma Margins & Growth Rates
Jiangsu Hengrui Pharma's revenue in the last 12 month grew by 15%.
Jiangsu Hengrui Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Jiangsu Hengrui Pharma's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangsu Hengrui Pharma's rule of X is 65% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jiangsu Hengrui Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jiangsu Hengrui Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zoetis | XXX | XXX | XXX | XXX | XXX | XXX |
| UCB | XXX | XXX | XXX | XXX | XXX | XXX |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Takeda Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| argenx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Hengrui Pharma M&A Activity
Jiangsu Hengrui Pharma acquired XXX companies to date.
Last acquisition by Jiangsu Hengrui Pharma was on XXXXXXXX, XXXXX. Jiangsu Hengrui Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jiangsu Hengrui Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJiangsu Hengrui Pharma Investment Activity
Jiangsu Hengrui Pharma invested in XXX companies to date.
Jiangsu Hengrui Pharma made its latest investment on XXXXXXXX, XXXXX. Jiangsu Hengrui Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jiangsu Hengrui Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jiangsu Hengrui Pharma
| When was Jiangsu Hengrui Pharma founded? | Jiangsu Hengrui Pharma was founded in 1997. |
| Where is Jiangsu Hengrui Pharma headquartered? | Jiangsu Hengrui Pharma is headquartered in China. |
| How many employees does Jiangsu Hengrui Pharma have? | As of today, Jiangsu Hengrui Pharma has over 20K employees. |
| Is Jiangsu Hengrui Pharma publicly listed? | Yes, Jiangsu Hengrui Pharma is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma trades under 600276 ticker. |
| When did Jiangsu Hengrui Pharma go public? | Jiangsu Hengrui Pharma went public in 2000. |
| Who are competitors of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma main competitors are Zoetis, UCB, CSL, Takeda Pharmaceuticals. |
| What is the current market cap of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's current market cap is $52B. |
| What is the current revenue of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's last 12 months revenue is $5B. |
| What is the current revenue growth of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Jiangsu Hengrui Pharma? | Current revenue multiple of Jiangsu Hengrui Pharma is 9.8x. |
| Is Jiangsu Hengrui Pharma profitable? | Yes, Jiangsu Hengrui Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's last 12 months EBITDA is $1B. |
| What is Jiangsu Hengrui Pharma's EBITDA margin? | Jiangsu Hengrui Pharma's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Jiangsu Hengrui Pharma? | Current EBITDA multiple of Jiangsu Hengrui Pharma is 34.1x. |
| What is the current FCF of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's last 12 months FCF is $1B. |
| What is Jiangsu Hengrui Pharma's FCF margin? | Jiangsu Hengrui Pharma's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of Jiangsu Hengrui Pharma? | Current FCF multiple of Jiangsu Hengrui Pharma is 34.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.